secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-070901
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio Q1 cash $197.8M; pipeline on track for 2025 milestones
----------------------------------------------------------------

- Cash and marketable securities $197.8M; expected to fund operations through 2027.
- R&D expense $17.3M including $9.0M upfront to Mabworks for CLYM116 license.
- Budoprutug Phase 2 pMN FDA-cleared; ITP and SLE trials on track for H1 2025 initiation.
- CLYM116 IND/CTA submission expected H2 2025 with preclinical data in H2.
- Appointed Kim Drapkin and Bo Cumbo as independent directors; Perrin Wilson as CBO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/0000950170-25-070901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000095017025070901/clym-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer